Olimesta Combi (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olimesta Combi, is an angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in combination with a diuretic, and is intended for adult patients requiring blood‑pressure control. GNH USA supplies Olimesta Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olimesta Combi combines two antihypertensive agents that act on the renin‑angiotensin‑aldosterone system to lower blood pressure. - Hypertension: provides effective blood‑pressure reduction in patients who need combined ARB and thiazide therapy. - Resistant hypertension: adds diuretic effect to improve control when monotherapy is insufficient. - Edema associated with hypertension: helps reduce fluid retention through the diuretic component.

Adverse reactions may range from mild to serious and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Severe electrolyte imbalance - Allergic skin reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters. - Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: monitor potassium and sodium levels regularly. - Pregnancy: contraindicated in the second and third trimesters; avoid use. - Concomitant drugs: review for potential interactions, especially other antihypertensives. - Orthostatic hypotension: advise patients to rise slowly to reduce fall risk. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olimesta Combi may interact with several drug classes; careful review is essential.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: additive blood‑pressure lowering, risk of hypotension. - Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.